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Abstract
The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithro-
mycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this 
review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin 
in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in 
addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only 
as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agree-
ment. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use 
of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic 
potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxy-
chloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, 
recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have 
cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.
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Key Points 
Azithromycin has been proposed as a drug to treat 
COVID-19 infection, although this drug has torsado-
genic potential which is cause for concern, especially if 
concomitantly administered with hydroxychloroquine/
chloroquine
There is currently no evidence to support the efficacy 
of azithromycin treatment in COVID-19 infection, as 
completed trials are methodologically flawed and under-
powered
Major public health organisations, drug regulatory agen-
cies and scientific societies do not recommend the use 
of azithromycin as a drug to treat COVID-19 infection, 
unless bacterial superinfections occur
1 Introduction
The global COVID-19 pandemic has led to 9,400,295 
infected patients and 482,468 deaths worldwide between 
31st December 2019 and 25th June 2020, according to 
the European Centre for Disease Control [1]. This public 
health emergency has triggered a race to find medications 
to improve the prognosis of disease. In turn, this has led to a 
tug of war between proponents of the conservative approach 
of not using medications in COVID-19 infection unless their 
risk–benefit profile has been scientifically proven and the 
proponents of the non-conservative approach proposing 
to offer new treatment even in absence of strong scientific 
evidence, on the basis of clinical intuition or in vitro find-
ings only [2]. Making such decisions under the pressure of 
a pandemic is not easy. On one hand, scientific evidence is 
needed to confirm that the benefits of treatment outweigh 
the risks, but on the other hand, the clinical trials needed 
to do this can be difficult to plan, implement and ultimately 
generate robust scientific evidence in a short time. There is 
currently great interest in drug repurposing or repositioning 
to manage COVID-19 infection, that is, the evaluation of 
the usefulness of a drug for an indication different to that for 
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which it was marketed. One such case is the use of the mac-
rolide azithromycin, often in association with the disease-
modifying anti-rheumatic drugs hydroxychloroquine/chlo-
roquine, in COVID-19 patients. It is important to critically 
analyse the available evidence in favour or against the use of 
azithromycin, in particular in association with hydroxychlo-
roquine/chloroquine, in COVID-19 patients, both in terms of 
benefit and risk. At present, the World Health Organization 
(WHO) as well as the European Medicines Agency (EMA) 
have indicated the lack of evidence supporting the efficacy 
of any medication in COVID-19 [3, 4].
Clinical evidence on the antibacterial effect in commu-
nity-acquired pneumonia (CAP) as well as immunomodu-
lating and antiviral actions as a rationale for the use of 
azithromycin in COVID-19 are reviewed and prescribing 
guidelines discussed in detail. The main risks underlying 
the use of this antibacterial, that is, torsadogenic potential, 
especially in association with hydroxychloroquine/chloro-
quine, is also described.
2  The Potential Role of Azithromycin 
in COVID‑19 Infection: A Pharmacological 
Perspective
The strongest evidence of effectiveness for azithromycin 
concerns its role as an antibacterial drug. Although there 
is no direct evidence of the effectiveness of azithromycin 
in COVID-19, some scientific bodies have suggested that 
the antibacterial properties of azithromycin remain clini-
cally useful in the empirical treatment of CAP occurring 
in COVID-19 patients. Not all current treatment guidelines 
agree on azithromycin use in CAP. There is weak evidence 
on the antiviral and immunomodulating effects of azithro-
mycin, which in addition was not derived from persons 
with COVID-19 specifically. The available evidence is 
discussed below.
2.1  Antibacterial Effect in Bacterial 
Community‑Acquired Pneumonia
In most patients with suspected or confirmed SARS-CoV-2 
infection, lung damage correlates with the severity of viral 
infection; however, bacterial co-infection has been reported 
in several patients affected by COVID-19 pneumonia [5–7]. 
Thus, some guidelines have been adapted in the context of 
the COVID-19 pandemic to promote the appropriate use of 
antibiotics and to delineate the role of these drugs, including 
azithromycin, in COVID-19 patients.
The United Kingdom’s National Institute for Health and 
Care Excellence (NICE) has developed a guideline aiming 
to improve antibiotic prescribing in COVID-19 patients with 
concomitant bacterial CAP or hospital-acquired pneumonia 
(HAP) [8]. In the absence of bacterial co-infection, antibi-
otic therapy is contraindicated for COVID-19 pneumonia, 
because it would be ineffective, considering its viral aetiol-
ogy. Therefore, according to NICE the use of antibiotics 
should be limited only to the management of those situations 
in which bacterial pulmonary co-infections are suspected 
or confirmed. The decision-making process in choosing 
antibiotic therapy should be based on clinical tests, such 
as microbiological tests, chest imaging, complete blood 
count, urine tests for legionella and pneumococcal anti-
gens. Moreover, for the treatment of severe bacterial CAP in 
COVID-19 patients, the NICE guideline suggests the use of 
clarithromycin among macrolide antibiotics, in association 
with co-amoxiclav, orally or intravenously, or in co-admin-
istration with cefuroxime as an alternative to co-amoxiclav. 
Although, in a systematic review, it was found that the clini-
cal efficacy and number of adverse events of azithromycin 
was not significantly different from clarithromycin in adults 
with low- to moderate-severity CAP [9], azithromycin is 
not recommended for the treatment of CAP or HAP in the 
NICE guideline because its long half-life could increase the 
risk of antibacterial resistance [10]. However, in another 
guideline on the treatment of bacterial CAP in COVID-19 
patients proposed by the American Thoracic Society (ATS) 
and Infectious Diseases Society (IDS), antibiotic macrolides 
are recommended as first-line therapy in combination with 
β-lactams in low-risk patients, and both azithromycin and 
clarithromycin are indicated [5].
The use of azithromycin alone to prevent bacterial co-
infections in COVID-19 patients is not supported by the 
above-mentioned guidelines adapted for the SARS-CoV-2 
pandemic. According to the NICE guidelines, antibiotic 
therapy should be limited only to COVID-19 patients 
where bacterial co-infection is suspected or confirmed [8].
2.2  Immunomodulating Effect
Since cytokine release syndrome (CRS), also known as 
cytokine storm, seems to be a major driver of mortality in 
COVID-19, several drugs with immunomodulating activity 
have been proposed as potential agents to be repurposed 
for the treatment of COVID-19 patients [11]. Indeed, 
several immunomodulatory effects of azithromycin have 
been found in many experimental studies [12–14]. It has 
been demonstrated that in mammalian cells, azithromycin 
influences intracellular mitogen-activated protein kinase 
(MAPK), in particular extracellular signal-regulated 
kinases 1/2 (ERK1/2) and the NF-κB pathway downstream 
of ERK [12]. Because these pathways are involved in many 
cellular functions, including inflammatory cytokine pro-
duction, cell proliferation and mucin secretion, effects 
on ERK1/2 and NF-κB can explain most of the reported 
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immunomodulatory effects of the macrolides [12]. Due to 
these immunomodulatory effects, azithromycin has proven 
effective in the management of several chronic lung dis-
eases, such as cystic fibrosis (CF), non-CF bronchiectasis, 
chronic obstructive pulmonary disease, chronic rhinosi-
nusitis, sepsis and diffuse panbronchiolitis [12, 13].
In murine experimental models of Pseudomonas aer-
uginosa lung infection and lipopolysaccharide-induced 
inflammation, studies described a reduction of lung leu-
kocytes, inflammatory cytokines, levels of myeloper-
oxidase, tumour necrosis factor (TNF)-α and interleukin 
(IL)-1β and a change of macrophage activation [12, 14]. 
The cytokine storm and the excessive immunological 
response are considered to be the main cause of morbid-
ity and mortality in viral pneumonia caused by the severe 
acute respiratory syndrome (SARS) and MERS coronavi-
ruses, as well as for SARS-CoV-2. Therefore, modulation 
of the inflammatory response may theoretically reduce the 
complications of viral pneumonia [11]. However, the use 
of immunomodulatory agents, such as corticosteroids, in 
patients with SARS has not shown significant beneficial 
effects [15]. However, very recently announced results 
from the Oxford University Recovery Trial seem to sug-
gest that dexamethasone reduced mortality among patients 
receiving invasive mechanical ventilation or oxygen, but 
not among those not receiving respiratory support [16]. 
There is also no evidence that the use of azithromycin in 
COVID-19 mitigates the cytokine storm.
2.3  Antiviral Effect
Azithromycin is also thought to have antiviral properties 
that may work in synergy with antiviral drugs. Preclini-
cal studies have found that this macrolide antibiotic can 
exert antiviral effects against Zika virus, rhinovirus and 
Ebola virus [17–20]. However, antiviral effects specifically 
in COVID-19 patients have not yet been demonstrated. 
Clinical studies on the use of azithromycin in patients with 
pneumonia caused by respiratory viruses had conflicting 
findings. In a multi-centre, open-label, randomised clinical 
trial conducted among patients with influenza A, a combi-
nation therapy of osteltamivir plus azithromycin (2 g/day, 
extended-release formulation) was associated with improve-
ment of some influenza-related symptoms, but with no dif-
ference in inflammatory cytokine levels [21]; furthermore, 
the azithromycin dosage used in this study was higher than 
that recommended by the ATS guideline. There is also lim-
ited evidence concerning the usefulness of azithromycin in 
viral infections that are similar to COVID-19 infection. A 
retrospective cohort study conducted in 14 tertiary-care hos-
pitals in five cities in Saudi Arabia from 2012 to 2018 [22] 
demonstrated that in 349 patients with laboratory-confirmed 
Middle-East Respiratory Syndrome (MERS), caused by a 
coronavirus similar to SARS-COV-2, treatment with mac-
rolides (97 patients treated with azithromycin, 28 treated 
with clarithromycin and 22 treated with erythromycin) was 
not associated with a reduction in 90-day mortality (adjusted 
odds ratio 0.84; 95% confidence interval (CI) 0.47–1.51; 
p = 0.56) or improvement in MERS-CoV RNA clearance 
(adjusted hazard ratio 0.88; 95% CI 0.47–1.64; p = 0.68). 
To date, there is no robust evidence on the effectiveness 
of azithromycin (plus hydroxychloroquine/chloroquine) for 
COVID-19, alone or in combination, even for the treatment 
of viral infections similar to SARS-CoV-2.
3  Clinical Evidence on the Role 
of Azithromycin in COVID‑19 Patients
The main clinical ‘evidence’ concerning the benefit of 
azithromycin with or without hydroxychloroquine or chlo-
roquine in COVID-19 infection comes from an open-label 
non-randomised trial in France recruiting 42 hospitalised 
persons with COVID-19 over 14 days. Patients were treated 
with hydroxychloroquine 600 mg daily with add-on azithro-
mycin (500 mg on day 1 followed by 250 mg per day for 
the next 4 days) in six patients to prevent bacterial super-
infection. The investigators found that on day 6 after enrol-
ment, 100% of patients treated with hydroxychloroquine 
and azithromycin (n = 6) had no detectable viral load, com-
pared with 57.1% in patients treated with hydroxychloro-
quine monotherapy (n = 14) and 12.5% in the control group 
(n = 16) (p < 0.001). There are several methodological issues 
with this paper that have been described in detail elsewhere, 
including poor reporting, missing PCR data and unjustified 
exclusion of patients with clinically important outcomes 
[23]. These limitations critically affect the quality of this 
study, making the reliability of the results obtained question-
able. A conflicting finding was reported in a recent small 
French study on eleven COVID-19 patients who were treated 
with hydroxychloroquine plus azithromycin, at the same dos-
age used by Gautret et al. Of these 11 patients, one died, two 
were transferred to intensive care and one developed a pro-
longation of QT interval and interrupted the treatment. By 
the end of the study, eight patients (73%) were still positive 
for SARS-CoV-2, 5–6 days after the start of treatment [24]. 
Like the trial by Gautret et al., this trial was also limited by 
the very small population and the lack of randomisation. A 
recent observational study has also raised concerns about the 
benefits of hydroxychloroquine/chloroquine, used alone or 
with a macrolide, in COVID-19 patients. One study enrolled 
1438 hospitalised patients with a diagnosis of COVID-19. 
Of these, 735 (51.1%) received hydroxychloroquine plus 
azithromycin, 271 (18.8%) received hydroxychloroquine 
alone, 211 (14.7%) were treated with azithromycin alone 
and 221 (15.4%) were treated with other drugs. Adjusted 
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statistical analyses showed no significant differences in in-
hospital mortality for patients receiving hydroxychloroquine 
plus azithromycin, hydroxychloroquine alone or azithromy-
cin alone, compared with patients receiving neither drug 
[25].
Major scientific societies, drug regulatory agencies and 
public health organisations have not recommended the use of 
azithromycin in COVID-19, to our knowledge. For example, 
the WHO and EMA have not issued any statement about 
the safety and efficacy of this combination in COVID-19 
infection. The Italian Drug Agency (AIFA) stated that the 
use of azithromycin, alone or in combination with hydroxy-
chloroquine/chloroquine, for the treatment of COVID-19 
patients is not recommended, unless bacterial superinfec-
tions occur [26]. However, the benefit–risk profile of these 
drugs in COVID-19 patients is still coming to light. To date 
there are 20 ongoing clinical trials concerning the use of 
azithromycin, alone or in combination with other drugs, in 
COVID-19 registered in clinicaltrials.gov.
4  Torsadogenic Effects of Azithromycin
Given the limited evidence on the benefits of azithromy-
cin (with or without hydroxychloroquine/chloroquine) in 
COVID-19 patients or even as a first-line agent for CAP, it 
is imperative to weigh its risks. Some macrolides are well 
known to be arrhythmogenic, notably erythromycin [27–32]. 
Azithromycin is believed to be one of the safest macrolides 
[33] but there is conflicting information on the risk of 
arrhythmia. At the pre-clinical level, the proarrhythmogenic 
effects of azithromycin were investigated in different animal 
models (guinea pigs, rabbits and dogs), showing that azithro-
mycin is not associated with torsades de pointes (TdP) or 
early afterdepolarisations, although this drug increases QT 
interval and monophasic action potential duration [34–36].
Clinical studies suggest that azithromycin does not alter 
the risk of cardiac events as was shown in two randomised 
controlled trials evaluating the efficacy of antibiotic therapy 
with azithromycin for the secondary prevention of coronary 
events [37]. These results were further confirmed by two 
meta-analyses of randomised clinical trials showing that 
azithromycin was not significantly associated with either a 
reduction of the frequency of recurrent cardiac events [38] or 
with an increased risk for mortality or cardiovascular events 
in patients with coronary artery disease [39]. However, there 
are several case reports describing QT-interval prolongation 
[40–42], TdP [43–45] and polymorphic ventricular tachycar-
dia [46] during treatment with azithromycin. These proar-
rhythmogenic effects are pharmacologically plausible [47].
Moreover, there is evidence from post-marketing sur-
veillance data supporting concerns about the potential 
torsadogenic effects azithromycin. A pharmacovigilance 
study analysed the FDA Adverse Event Reporting System 
(FAERS) from 2004 to 2011 and identified a total of 203 
reports of arrhythmia-related events (e.g. QT prolongation, 
TdP, ventricular arrhythmia, sudden cardiac death) associ-
ated with azithromycin [48]. The public version of Eudrav-
igilance, the European Medicines Agency’s Adverse Drug 
Reactions (ADR) database (http://www.adrre ports .eu/en/
searc h.html), has 188, 87 and 55 cases of QT prolongation in 
patients treated with azithromycin, hydroxychloroquine and 
chloroquine, respectively, out of a total of 12,764, 15,129 
and 1644 reports for each suspected drug (Table 1). In addi-
tion, several observational studies investigated the associa-
tion of cardiovascular death (as a potential consequence 
of QT prolongation) with azithromycin use. These studies 
report conflicting evidence [49–56]. There is very limited 
and contrasting real-world evidence concerning the risk of 
azithromycin use and ventricular arrhythmia [57–59].
In light of the above-mentioned data, caution is warranted 
if azithromycin is used concomitantly with chloroquine or 
hydroxychloroquine to treat COVID-19, as both drugs have 
known risk of TdP [60]. There is increasing and contrasting 
data evaluating the safety of combination therapy. A recent 
observational study evaluated the effects of the association 
of azithromycin with chloroquine or hydroxychloroquine 
on QT interval in 201 COVID-19 patients. Of these, ten 
patients (5.0%) received chloroquine, 191 (95.0%) were 
treated with hydroxychloroquine and 119 (59.2%) also 
received azithromycin. The authors found that, although 
the maximum QT during treatment was significantly longer 
in the combination group compared with the monotherapy 
group (470.4 ± 45.0 ms vs 453.3 ± 37.0 ms; p = 0.004), no 
instances of TdP or arrhythmogenic death were reported 
[61]. However, these findings have been refuted by several 
recent studies evaluating the effects of this association on 
QT interval in COVID-19 patients. These studies indicate 
that the use of azithromycin with chloroquine/hydroxychlo-
roquine could significantly prolong QT interval, especially 
in patients affected by severe COVID-19 and in the presence 
of comorbidities, suggesting using this association with cau-
tion [62–66]. According to the Liverpool Drug Interactions 
group, electrocardiogram monitoring is recommended in 
patients treated with chloroquine/hydroxychloroquine and 
other QT-prolonging drugs including azithromycin [67]. No 
interactions are reported for other classes of antimicrobials 
such as penicillins or cephalosporins, which may therefore 
be a safer therapeutic alternative to azithromycin, even when 
combined with chloroquine/hydroxychloroquine.
The risks of combining torsadogenic drugs such as 
azithromycin and hydroxychloroquine/chloroquine were 
highlighted by several scientific societies or drug agencies. 
On 30 March 2020, the French drug safety agency (ANSM) 
warned of potentially serious side effects, in particular 
cardiac risk, of treatments being tested against the new 
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coronavirus (hydroxychloroquine and lopinavir/ritonavir) 
after the deaths of three people possibly linked to self-med-
ication. ANSM also pointed out how this cardiac risk could 
be increased by using hydroxychloroquine in association 
with other potentially torsadogenic drugs such as azithro-
mycin, or in patients with specific metabolic disorders (e.g. 
hypokalaemia) [68]. The American College of Cardiology 
(ACC) noted that COVID-19-infected patients are likely to 
have longer baseline QTc and higher potential arrhythmic 
risks as a result of the metabolic and physiologic sequelae 
of their illness, and a typically greater burden of comor-
bid disease [69]. Recently, the ACC suggested that safety 
concerns regarding the use of hydroxychloroquine–azithro-
mycin combination for COVID-19 should be considered 
in the context of several important mitigating factors, such 
as the short duration of treatment and the potential benefit 
among specific subgroups with COVID-19 infection (in 
particular, ICU-hospitalised patients with serious illness). 
Furthermore, the ACC highlighted that close monitoring and 
optimisation of known risk factors for TdP (e.g. structural 
heart disease, congenital long-QT syndromes, electrolyte 
disturbances, hepatic/renal failure, etc.) could maximise the 
safety of potential QT-prolonging medications [69]. Both 
AIFA and ACC stated that a clinical trial evaluating the 
effectiveness and safety of these drugs is urgently needed. 
Mayo Clinic has recently published its own recommenda-
tions for the treatment of COVID-19 patients with poten-
tially arrhythmogenic drugs. This guidance suggests that 
it is essential to identify the small subset of patients who, 
either due to a genetic predisposition and/or due to QT risk 
factors, have a high baseline risk of QT prolongation and/
or have an inherent tendency to develop an exaggerated QT 
response after being treated with QT-prolonging medica-
tions [70]. Elderly patients in particular may be at higher 
risk, especially because of the likelihood of being prescribed 
QT-prolonging drugs and of polypharmacy in this popula-
tion [71].
5  Conclusion
There is no clear evidence that azithromycin may exert ben-
eficial effects in COVID-19 beyond antibacterial activity in 
bacterial superinfection. In COVID-19 infection, empirical 
broad-spectrum antibiotic therapy should be chosen only 
to treat superinfection, preferably based on CAP treatment 
guidelines from scientific societies, which never recom-
mend macrolide use alone as first-line treatment. Although 
the arrhythmogenic potential of azithromycin is lower as 
compared with other macrolides or other antibacterial 
drug classes, such as fluoroquinolones, the use of drugs 
with even a low risk of arrhythmia with other potential 
QT-prolonging drugs such as hydroxychloroquine/chlo-
roquine warrants close electrocardiogram monitoring. If 
not possible, as may be the case in an outpatient setting, a 
thorough evaluation of potential risk factors for arrhythmia 
has to be considered with the ultimate goal to carefully 
weigh the risks against the benefits of different antibiotics 
for the treatment of bacterial superinfection in COVID-19 
patients.
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